Clinical Trial Detail

NCT ID NCT03436732
Title Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

malignant epithelial mesothelioma

malignant biphasic mesothelioma

peritoneal mesothelioma

Therapies

LMB-100 + SVP-rapa

Age Groups: adult senior

No variant requirements are available.